280
Photo: Getty Images (illustrative photo)
There is a shortage of medicines in Russia
In Russia, six preparations of anti-Rhesus immunoglobulin are registered, but the market is formed by four, three of which are of foreign production.
In Russia, there is an acute shortage of anti-Rhesus immunoglobulin, which is necessary for pregnant women with a negative Rh factor. The reason was a sharp reduction in supplies in 2024. This was reported by Russian media on Thursday, August 9.
According to the analytical company RNC Pharma, in the first six months of 2024, about 48 thousand packages of the drug came to the market, which is 71% less compared to the same period in 2023.
In Russia, six preparations of anti-Rhesus immunoglobulin are registered, but the market is formed by four, three of which are of foreign production. In 2023, the largest market share (49,2%) was occupied by the Italian drug "Imunoro Kedrion" from Kedrion Biopharm. The drug Kamrow from the Israeli company Kamada accounted for 32,5% of the market, and Rezogam N from the international company CSL Behring occupied 14%.
As reported by Kedrion Biopharm, the company's drug is "in limited supply", and its nearest supply will take place no earlier than the fourth quarter of 2024.
In February, the Ministry of Health of the Russian Federation doubled the price of "Imunoro Kedrion".
"That is why the drug will appear on the market again in the fourth quarter of 2024," Kedrion Biopharm said.
Delivery of Kamrow to Russia was carried out by Medical Research Company LLC. In 2023, the manufacturer terminated the contract with the distributor. The reason was, in particular, the insufficient price of the drug in Russia.
